StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Zavicefta (ceftazidime/avibactam by Quarter

Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — Worldwide operational (constant-currency) YoY (%) (%)

QuarterlyAnnual

Pfizer Zavicefta (ceftazidime/avibactam: 17.0% in Q2 2026, up 7.0 pts from a year earlier.

Latest, Q2 2026
17.0%
Period ended Jun 28, 2026
Change on a year earlier
+7.0 pts
10.0% in Q2 2025
History
20 quarters
Since Q4 2020
Sources
20
Documents cited below

Where the Q2 2026 figure comes from

“|| Zavicefta (Outside the U.S. and Canada) | 199 | 163 | 22% | 17% | — | — | — | 199 | 163 | 22% | 17%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — Worldwide operational (constant-currency) YoY (%) (%)Year on yearSource
Q2 2026Jun 28, 202617.0%+7.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 20263.0%-11.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 202510.0%-12.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 20253.0%-16.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 202510.0%-8.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2025Mar 30, 202514.0%+6.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2024Dec 31, 202422.0%-9.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2024Sep 29, 202419.0%-24.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2024Jun 30, 202418.0%-26.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 20248.0%-14.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2023Dec 31, 202331.0%+16.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2023Oct 1, 202343.0%+42.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2023Jul 2, 202344.0%–Form 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2023Apr 2, 202322.0%+5.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q4 2022Dec 31, 202215.0%-43.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
Q3 2022Oct 2, 20221.0%–Form 8-K (Earnings / Guidance Release) (pfe-10022022xex99.htm, filed 2022-11-01) ↗

Cite this data

StockData. (2026). Pfizer Zavicefta (ceftazidime/avibactam (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/zavicefta-oper-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.

See a number that looks wrong?